生物医药ETF（512290）连续5日资金净流入超2.2亿元，医药2026年或将呈现“科技先行，药械起飞”

Core Viewpoint - The article emphasizes that technological innovation will be the most significant trend in the pharmaceutical industry by 2026, with a focus on "technology first, medical devices take off" [1] Group 1: Innovative Drugs - The focus will be on revenue and performance realization, particularly on companies that exceed expectations in business development (BD) and cutting-edge technology platforms such as gene therapy, small nucleic acids, and universal/in vivo CAR-T [1] Group 2: Medical Devices - For medical devices, attention will be on inventory replenishment and bidding processes, particularly for surgical robots and endoscopes; consumables will benefit from centralized procurement, especially in innovative areas like neurointervention, peripheral intervention, and electrophysiology [1] Group 3: Changing Targets - With the central economic work conference highlighting the importance of domestic demand and building a strong domestic market, companies related to domestic pharmaceutical demand may experience a turning point [1] - Novartis' Pluvicto approval in China opens up possibilities for radioligand therapy (RDC), which, due to its different mechanism of action and high efficacy, may become a major direction in nuclear medicine development [1] Group 4: Biopharmaceutical ETF - The biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, and medical devices from the Shanghai and Shenzhen markets to reflect the overall performance of biopharmaceutical-related securities [1]